Clinical trial · Observational
S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT
Prostate Cancer Prevention Trial (PCPT) Companion Long Term Follow Up Study for Men Diagnosed With Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor accrual resulted in lack of feasibility to evaluate endpoints.
Summary
Brief summary (as posted)
RATIONALE: Learning about the long-term effects of chemoprevention drugs, such as finasteride, in patients with prostate cancer may help doctors plan better treatment and follow-up care. PURPOSE: This clinical trial is following patients who were diagnosed with prostate cancer while undergoing treatment with either finasteride or a placebo on the Prostate Cancer Prevention Trial (PCPT).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Follow-up | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Long Term Follow-Up
- description
- Follow-up data collection study for men who developed prostate cancer after participation in SWOG-9217 (PCPT)
- interventionNames
- Other: Follow-up
Primary outcomes (1)
- measure
- Time to metastases
- timeFrame
- Up to 8 years post registration
Secondary outcomes (3)
- measure
- Time to secondary therapy after definitive therapy
- timeFrame
- Up to 8 years post registration
- description
- Definitive therapy is defined as radiotherapy or radical prostatectomy.
- measure
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 55 Years
- Maximum age
- 120 Years
Show eligibility criteria text
INCLUSION CRITERIA: * Randomized on PCPT * Diagnosed with prostate cancer on or before December 31, 2003 DISEASE CHARACTERISTICS: * Diagnosed by either study site or central pathology review PATIENT CHARACTERISTICS: * See inclusion criteria PRIOR CONCURRENT THERAPY: * Not Applicable
References
Publications (1)
- DERIVEDChau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM, Chu L, Parnes HL, Schenk JM, Reichardt JK, Thompson IM, Figg WD. Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. PLoS One. 2015 May 8;10(5):e0126672. doi: 10.1371/journal.pone.0126672. eCollection 2015. PMID 25955319